FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044687690> ?p ?o ?g. }

• W3044687690 endingPage "2069" @default.
• W3044687690 startingPage "2069" @default.
• W3044687690 abstract "Lung cancer is the leading cause of cancer death worldwide and the therapeutic strategies include surgery, chemotherapy and radiation therapy. Non-small cell lung cancers (NSCLCs) account for around 85% of cases of lung cancers. Pemetrexed is an antifolate agent that is currently used as the second line chemotherapy drug in the treatment of advanced NSCLC patients with a response rate of 20–40%. The search for any combination therapy to improve the efficacy of pemetrexed is required. The existence of cancer stem cells (CSCs) is considered as the main reason for drug resistance of cancers. In this study, we first found that pemetrexed-resistant NSCLC cells derived from A549 cells displayed higher CSC activity in comparison to the parental cells. The expression of CSC related proteins, such as BMI1 or CD44, and the epithelial–mesenchymal transition (EMT) signature was elevated in pemetrexed-resistant NSCLC cells. We next discovered that the overexpression of BMI1 in A549 cells caused the pemetrexed resistance and inhibition of BMI1 by a small molecule inhibitor, PTC-209, or transducing of BMI1-specific shRNAs suppressed cell growth and the expression of thymidylate synthase (TS) in pemetrexed-resistant A549 cells. We further identified that BMI1 positively regulated SP1 expression and treatment of mithramycin A, a SP1 inhibitor, inhibited cell proliferation, as well as TS expression, of pemetrexed-resistant A549 cells. Furthermore, overexpression of BMI1 in A549 cells also caused the activation of EMT in and the enhancement of CSC activity. Finally, we demonstrated that pretreatment of PTC-209 in mice bearing pemetrexed-resistant A549 tumors sensitized them to pemetrexed treatment and the expression of Ki-67, BMI1, and SP1 expression in tumor tissues was observed to be reduced. In conclusion, BMI1 expression level mediates pemetrexed sensitivity of NSCLC cells and the inhibition of BMI1 will be an effective strategy in NSCLC patients when pemetrexed resistance has developed." @default.
• W3044687690 created "2020-07-29" @default.
• W3044687690 creator A5001037372 @default.
• W3044687690 creator A5014795553 @default.
• W3044687690 creator A5020517811 @default.
• W3044687690 creator A5062666996 @default.
• W3044687690 creator A5063687976 @default.
• W3044687690 creator A5088878540 @default.
• W3044687690 creator A5088936195 @default.
• W3044687690 date "2020-07-27" @default.
• W3044687690 modified "2023-10-17" @default.
• W3044687690 title "BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness" @default.
• W3044687690 cites W1554896841 @default.
• W3044687690 cites W1966383291 @default.
• W3044687690 cites W1973663958 @default.
• W3044687690 cites W1983011271 @default.
• W3044687690 cites W1983347286 @default.
• W3044687690 cites W1984543805 @default.
• W3044687690 cites W1989149125 @default.
• W3044687690 cites W1999817838 @default.
• W3044687690 cites W2002038028 @default.
• W3044687690 cites W2010858399 @default.
• W3044687690 cites W2014128254 @default.
• W3044687690 cites W2018439279 @default.
• W3044687690 cites W2018569307 @default.
• W3044687690 cites W2028319373 @default.
• W3044687690 cites W203645465 @default.
• W3044687690 cites W2037139573 @default.
• W3044687690 cites W2041921905 @default.
• W3044687690 cites W2054686270 @default.
• W3044687690 cites W2060774265 @default.
• W3044687690 cites W2083189837 @default.
• W3044687690 cites W2094314204 @default.
• W3044687690 cites W2099725888 @default.
• W3044687690 cites W2102627969 @default.
• W3044687690 cites W2112621029 @default.
• W3044687690 cites W2119805434 @default.
• W3044687690 cites W2131664752 @default.
• W3044687690 cites W2134667653 @default.
• W3044687690 cites W2138048815 @default.
• W3044687690 cites W2140674545 @default.
• W3044687690 cites W2144886407 @default.
• W3044687690 cites W2150479858 @default.
• W3044687690 cites W2158255028 @default.
• W3044687690 cites W2218527356 @default.
• W3044687690 cites W2284683492 @default.
• W3044687690 cites W2308408790 @default.
• W3044687690 cites W2409466177 @default.
• W3044687690 cites W2478564326 @default.
• W3044687690 cites W2479121739 @default.
• W3044687690 cites W2548971289 @default.
• W3044687690 cites W2567135770 @default.
• W3044687690 cites W2593074826 @default.
• W3044687690 cites W2607136031 @default.
• W3044687690 cites W2626043568 @default.
• W3044687690 cites W2724159286 @default.
• W3044687690 cites W2729738977 @default.
• W3044687690 cites W2781525129 @default.
• W3044687690 cites W2792310468 @default.
• W3044687690 cites W2800852522 @default.
• W3044687690 cites W2804704415 @default.
• W3044687690 cites W2909429444 @default.
• W3044687690 cites W2921889500 @default.
• W3044687690 cites W2922211740 @default.
• W3044687690 cites W2971698199 @default.
• W3044687690 cites W2986790007 @default.
• W3044687690 cites W3021013914 @default.
• W3044687690 doi "https://doi.org/10.3390/cancers12082069" @default.
• W3044687690 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7463866" @default.
• W3044687690 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32726929" @default.
• W3044687690 hasPublicationYear "2020" @default.
• W3044687690 type Work @default.
• W3044687690 sameAs 3044687690 @default.
• W3044687690 citedByCount "18" @default.
• W3044687690 countsByYear W30446876902021 @default.
• W3044687690 countsByYear W30446876902022 @default.
• W3044687690 countsByYear W30446876902023 @default.
• W3044687690 crossrefType "journal-article" @default.
• W3044687690 hasAuthorship W3044687690A5001037372 @default.
• W3044687690 hasAuthorship W3044687690A5014795553 @default.
• W3044687690 hasAuthorship W3044687690A5020517811 @default.
• W3044687690 hasAuthorship W3044687690A5062666996 @default.
• W3044687690 hasAuthorship W3044687690A5063687976 @default.
• W3044687690 hasAuthorship W3044687690A5088878540 @default.
• W3044687690 hasAuthorship W3044687690A5088936195 @default.
• W3044687690 hasBestOaLocation W30446876901 @default.
• W3044687690 hasConcept C121608353 @default.
• W3044687690 hasConcept C123321153 @default.
• W3044687690 hasConcept C126322002 @default.
• W3044687690 hasConcept C143998085 @default.
• W3044687690 hasConcept C1491633281 @default.
• W3044687690 hasConcept C2776256026 @default.
• W3044687690 hasConcept C2776694085 @default.
• W3044687690 hasConcept C2777240266 @default.
• W3044687690 hasConcept C2778239845 @default.
• W3044687690 hasConcept C2778987575 @default.
• W3044687690 hasConcept C2780456651 @default.
• W3044687690 hasConcept C2780932548 @default.

• next